Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-Current Debt (2020 - 2021)

Mereo BioPharma (MREO) has disclosed Non-Current Debt for 2 consecutive years, with $19.4 million as the latest value for Q4 2021.

  • On a quarterly basis, Non-Current Debt fell 9.03% to $19.4 million in Q4 2021 year-over-year; TTM through Dec 2021 was $19.4 million, a 9.03% decrease, with the full-year FY2021 number at $19.4 million, down 6.46% from a year prior.
  • Non-Current Debt was $19.4 million for Q4 2021 at Mereo BioPharma, down from $21.3 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $21.3 million in Q4 2020 to a low of $19.4 million in Q4 2021.